Eli Lilly agreed to acquire CrossBridge Bio in a deal valued at up to $300 million, strengthening Lilly’s antibody-drug conjugate (ADC) toolkit. CrossBridge develops next-generation ADCs built around dual-payload strategies intended to widen the therapeutic index and improve response durability. Lilly will pay an upfront cash component and additional consideration tied to development milestones, according to deal terms disclosed by both sides. CrossBridge’s lead candidate, CBB-120, is designed to target TROP2 using two cytotoxic payloads; the asset has not yet entered clinical testing at the time of announcement. For Lilly, the acquisition builds on its recent ADC strategy, adding another source of pipeline differentiation as ADCs continue moving into earlier lines of treatment.